CG Oncology, Inc.: Promising Outlook with Strong Clinical Performance and Strategic BLA Submission

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on CGON stock, giving a Buy rating today.

Tyler Van Buren has given his Buy rating due to a combination of factors that highlight CG Oncology, Inc.’s promising outlook. The company’s creto therapy has shown a strong clinical performance, particularly in the BCG-unresponsive, high-risk NMIBC category, achieving a 24-month complete response rate (CRR) of 34%, which is considered best-in-disease. This performance is significantly better than competing therapies, such as TAR-200, which only achieved a 24-month CRR of approximately 17%.
Furthermore, CG Oncology is preparing to initiate the Biologics License Application (BLA) submission in the second half of the year, aiming for a broad label that includes additional durability metrics. This strategic move is expected to provide marketing advantages over competitors. Additionally, the company is streamlining its administration process and conducting studies to enhance its product’s appeal, which could further strengthen its market position. These developments, along with the anticipated completion of enrollment for the pivotal IR trial by year-end, contribute to the positive outlook and justify the Buy rating.

According to TipRanks, Van Buren is an analyst with an average return of -4.6% and a 38.02% success rate. Van Buren covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Regeneron, and Moderna.

In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $75.00 price target.